Meet-the-Professor Session:
18. Which Is It?: The Colistin Versus Polymyxin B Debate
Thursday, October 27, 2016: 7:00 AM-8:15 AM
Room: 278-282

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the variables to consider when choosing the optimal drug for colistin and Polymyxin Β for select infection sites and patient populations
  • discuss the optimal dosing strategy for colistin and Polymyxin B

Target Audience: Academicians, Clinicians, Fellows, Infectious diseases pediatricians, Infectious diseases physicians, Members-in-training, Pharmacists

Tracks: Pediatric ID, Adult ID

Moderators:  David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health and Deborah Goff, PharmD, Ohio State University

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours 0.125 of pharmacy CE

ACPE Number: 0221-9999-16-207-L01-P


D. R. Andes, Astellas, Roche, Melinta, Actelion, Theravance, Paratek, Zavante, Scynexis: Grant Investigator , Grant recipient
Actelion, Melinta, Scynexis, Roche, Theravance, Meiji: Consultant , Consulting fee

D. Goff, Allergan: Scientific Advisor , Consulting fee
Cepheid: Scientific Advisor , Consulting fee
Merck: Speaker's Bureau , Speaker honorarium
Astellas: Speaker's Bureau , Speaker honorarium
Medicine Company: Scientific Advisor , Consulting fee

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.